News
Astellas reports Xospata + azacitidine did not meet the endpoint of overall survival in newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Astellas Pharma Inc. announced that a Phase III trial of Xospata (gilteritinib) plus azacitidine versus azacitidine alone in newly diagnosed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia (AML) patients who were ineligible for intensive induction chemotherapy did not meet its primary endpoint of overall survival > at a planned interim analysis of the LACEWING trial.
An independent Data Monitoring Committee recommended terminating the study for futility, concluding results are unlikely to show a statistically significant increase in overall survival . Astellas has stopped enrollment in the trial and is reviewing the results for other action as needed.
Condition: Acute Myelogeous Leukemia (AML)
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins